RALEIGH, N.C.–(BUSINESS WIRE)–Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced the appointment of Jeff Hartness to its Board of Directors. Mr. Hartness joins a group of senior directors focused on commercialization.
“Jeff’s diverse background crosses all channels and segments of pharmaceutical business making him a perfect fit to continue to strengthen our team’s commercial expertise,” said Michelle Lobel, Co-Founder of Bryn Pharma. “We look forward to working with Jeff and the rest of the Board as we continue to enhance our commercial planning for UTULY.”
Mr. Hartness brings more than 25 years of leadership and success in creating and executing go-to-market strategies in the healthcare space to Bryn’s Board. He has launched dozens of products in disease states including small molecules, specialty/biologics, devices, OTCs and generics. He is currently a member of Bausch Health Company’s (BHC) Global Executive Committee as Senior Vice President and Head of Market Access, Commercial Operations, Policy and Government Affairs. In this role, he focuses on the commercialization strategy of pricing, contracting and the creation of patient access to Bausch Health products, as well as the distribution of those products throughout the healthcare system. Prior to joining Bausch Health, Mr. Hartness spent 15 years at Sanofi in various leadership roles, including Product Launch Execution and as the Head of Pharmacy Benefit Managers, Employers and Specialty business. Mr. Hartness currently serves on the Board of Directors for Corganics, a privately held clinical cannabinoid life sciences company based in Dallas, Texas.
“Jeff brings a deep knowledge of the ever-changing and complex payer, market and government landscape that are critical to ensure patients and physicians have access to needed innovative products,” said David Dworaczyk, Ph.D., CEO of Bryn Pharma. “We are thrilled to welcome him to our esteemed Board.”
About Bryn Pharma
Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit www.brynpharma.com.
Contacts
Rebecca Novak Tibbitt
Rebecca@RNTCommunications.com